卡德萊蒂斯公司
DE ˙ DB ˙ US14161W1053
€0.49 ↓ -0.01 (-2.80%)
2026-06-04
分享價格
SecurityDE:CYX / Cardlytics, Inc.
InstitutionVanguard Group Inc
Latest Disclosed Ownership2,416,909 shares
Ownership 4.60%
Vanguard Group Inc ownership in CYX / Cardlytics, Inc.

2025-07-29 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,416,909 shares of Cardlytics, Inc. (DE:CYX). This represents 4.6 percent ownership of the company. In their previous filing dated 2024-02-13 , Vanguard Group Inc had reported owning 2,153,790 shares, indicating an increase of 12.22 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-07-29 2025-07-29 13G/A 2,153,790 2,416,909 12.22 4.60 -16.21
2024-02-13 2024-02-13 13G/A 2,392,757 2,153,790 -9.99 5.49 -23.86
2023-02-09 2023-02-09 13G/A 2,905,042 2,392,757 -17.63 7.21 -17.41
2022-02-09 2022-02-09 13G/A 1,836,743 2,905,042 58.16 8.73 30.49
2021-02-10 2021-02-10 13G 1,836,743 6.69

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F CARDLYTICS COM 14161W105 2,609,787 208,351 8.68 3,001 -48.57 0.0000
2025-11-07 2025-09-30 13F CARDLYTICS COM 14161W105 2,401,436 -15,473 -0.64 5,835 46.79 0.0001
2025-08-11 2025-06-30 13F CARDLYTICS COM 14161W105 2,416,909 -251,216 -9.42 3,976 -18.13 0.0001
2025-05-09 2025-03-31 13F CARDLYTICS COM 14161W105 2,668,125 -23,310 -0.87 4,856 -51.38 0.0001
2025-02-11 2024-12-31 13F CARDLYTICS COM 14161W105 2,691,435 22,620 0.85 9,985 16.92 0.0002
2024-11-13 2024-09-30 13F CARDLYTICS COM 14161W105 2,668,815 256,266 10.62 8,540 -56.88 0.0002
2024-08-13 2024-06-30 13F CARDLYTICS COM 14161W105 2,412,549 200,954 9.09 19,807 -38.19 0.0004
2024-05-10 2024-03-31 13F CARDLYTICS COM 14161W105 2,211,595 57,805 2.68 32,046 61.55 0.0006
2024-03-11 2023-12-31 13F/A-1 CARDLYTICS COM 14161W105 2,153,790 142,085 7.06 19,836 -40.24 0.0004
2024-02-14 2023-12-31 13F CARDLYTICS COM 14161W105 2,153,790 142,085 19,836 0.0004
2023-12-18 2023-09-30 13F/A-1 CARDLYTICS COM 14161W105 2,011,705 231,303 12.99 33,193 195.00 0.0008
2023-11-14 2023-09-30 13F CARDLYTICS COM 14161W105 2,011,705 231,303 33,193 0.0008
2023-08-14 2023-06-30 13F CARDLYTICS COM 14161W105 1,780,402 1,900 0.11 11,252 86.35 0.0003
2023-07-14 2023-03-31 13F/A-1 CARDLYTICS COM 14161W105 1,778,502 -614,255 -25.67 6,038 -56.34 0.0002
2023-05-15 2023-03-31 13F CARDLYTICS COM 14161W105 1,778,502 -614,255 6,038 0.0002
2023-02-10 2022-12-31 13F CARDLYTICS COM 14161W105 2,392,757 -619,655 -20.57 13,830 -51.16 0.0004
2022-11-14 2022-09-30 13F CARDLYTICS COM 14161W105 3,012,412 53,565 1.81 28,317 -57.10 0.0008
2022-08-12 2022-06-30 13F CARDLYTICS COM 14161W105 2,958,847 30,412 1.04 66,012 -59.00 0.0019
2022-05-13 2022-03-31 13F CARDLYTICS COM 14161W105 2,928,435 23,393 0.81 161,005 -16.14 0.0038
2022-02-14 2021-12-31 13F CARDLYTICS COM 14161W105 2,905,042 20,232 0.70 191,994 -20.71 0.0044
2021-11-12 2021-09-30 13F CARDLYTICS COM 14161W105 2,884,810 23,253 0.81 242,151 -33.33 0.0060
2021-08-13 2021-06-30 13F CARDLYTICS COM 14161W105 2,861,557 127,044 4.65 363,217 21.08 0.0090
2021-05-14 2021-03-31 13F CARDLYTICS COM 14161W105 2,734,513 897,770 48.88 299,976 14.39 0.0081
2021-02-12 2020-12-31 13F CARDLYTICS COM 14161W105 1,836,743 504,805 37.90 262,231 178.98 0.0076
2020-11-16 2020-09-30 13F CARDLYTICS COM 14161W105 1,331,938 48,504 3.78 93,995 4.65 0.0031
2020-08-14 2020-06-30 13F CARDLYTICS COM 14161W105 1,283,434 212,351 19.83 89,815 139.85 0.0032
2020-05-15 2020-03-31 13F CARDLYTICS COM 14161W105 1,071,083 28,284 2.71 37,446 -42.87 0.0016
2020-02-14 2019-12-31 13F CARDLYTICS COM 14161W105 1,042,799 79,332 8.23 65,550 102.97 0.0022
2019-11-14 2019-09-30 13F CARDLYTICS COM 14161W105 963,467 208,335 27.59 32,296 64.62 0.0012
2019-08-14 2019-06-30 13F CARDLYTICS COM 14161W105 755,132 238,211 46.08 19,618 129.45 0.0007
2019-05-15 2019-03-31 13F CARDLYTICS COM 14161W105 516,921 19,343 3.89 8,550 58.69 0.0003
2019-02-14 2018-12-31 13F CARDLYTICS COM 14161W105 497,578 92,376 22.80 5,388 -46.90 0.0002
2018-12-13 2018-09-30 13F/A-2 CARDLYTICS COM 14161W105 405,202 138,224 51.77 10,146 74.66 0.0004
2018-11-23 2018-09-30 13F/A-1 CARDLYTICS COM 14161W105 405,202 0 10,146 0.0004
2018-11-14 2018-09-30 13F CARDLYTICS COM 14161W105 405,202 138,224 10,146
2018-08-14 2018-06-30 13F CARDLYTICS COM 14161W105 266,978 83,343 45.39 5,809 116.19 0.0002
2018-05-15 2018-03-31 13F CARDLYTICS COM 14161W105 183,635 183,635 2,687 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.